PlasmidFactory expands lab capacities
PlasmidFactory GmbH & Co. KG announces that it has acquired new laboratory space for research and development as well as for the highly documented production of plasmid DNA, and has begun reconstructing and equipping the same.
"New capabilities are the key to helping our customers move to clinical trials of innovative vector systems, e.g. in the areas of CAR-T cell therapy and gene therapy", explains Managing Director Martin Schleef and adds, "Our research and development department (R & D) also urgently needs more space, as we have recently started new projects with our cooperation partners (for example with the University of Bielefeld)."
The extension of the facilities has become necessary, above all, due to the increasing demand for High Quality (HQ) Grade DNA production. As a result, HQ's laboratory capacity has been doubled and additional staff will be hired. Dr. Schleef says that in addition to the acquisition of new fermenters, the downstream processing capacity will be expanded with new chromatography systems and analytical equipment. In the growing field of gene and cell therapy, it is increasingly important to have high purity starting material for e.g. the production of viral vectors, CAR-T cells or RNA within (pre-) clinical studies. Therefore, demand for PlasmidFactory's High Quality Grade DNA is also increasing. This manufacturing process is operated in special dedicated laboratories. The process is extensively documented and the product undergoes numerous quality controls. The existing HQ laboratory area alone is no longer sufficient for this.
The expansion of the laboratory space benefits both, HQ production and research and development, and ultimately the customers and cooperation partners.
Other news from the department manufacturing
